Oral Contraceptive Clinical Trial
Official title:
A Multicenter, Open-Label Study to Evaluate Ovarian Follicular Activity and Hormone Levels With the Oral Contraceptive Regimen DR-102 Compared to Two 28-day Oral Contraceptive Regimens Containing Different Synthetic Progestins
This study is being conducted to evaluate the impact of a 28-day oral contraceptive compared to two 28-day oral contraceptive regimens containing different synthetic progestins on ovarian follicular activity and hormone levels in healthy women.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01388491 -
A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women
|
Phase 2 | |
Completed |
NCT01252186 -
A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women
|
Phase 2 | |
Not yet recruiting |
NCT06426459 -
Social Media Usage in Adolescent Girls
|
||
Recruiting |
NCT02398903 -
Evaluation of Hormonal Contraceptive Treatments in Obese Women
|
||
Completed |
NCT00302666 -
Bleeding Pattern Study
|
Phase 3 | |
Completed |
NCT00739622 -
TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.
|
Phase 1 | |
Recruiting |
NCT01318005 -
Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation
|
N/A | |
Recruiting |
NCT02021097 -
Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception
|
Phase 3 | |
Completed |
NCT00778609 -
Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache
|
Phase 3 | |
Completed |
NCT00972439 -
Oral Contraceptive (OC) Progestin Dose and Breast Proliferation
|
N/A | |
Completed |
NCT01076582 -
Comparative Trial in Hormone Withdrawal Associated Symptoms
|
Phase 3 | |
Completed |
NCT00471991 -
Valette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition
|
Phase 2 | |
Completed |
NCT00248963 -
Study Evaluating Levonorgestrel and Ethinyl Estradiol in Oral Contraception
|
Phase 3 |